2023-504792-24-00已完成1 期
A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
EU Submission Hub
Scientific
Novo Nordisk A/S
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.2023-509483-20-00Novo Nordisk A/S150
已完成
1 期
A study of how CagriSema works on appetite in people with excess body weightObesity2023-504782-23-00Novo Nordisk A/S150
招募中
3 期
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesDiabetes Mellitus, Type 2NCT07282613Novo Nordisk A/S80
撤回
2 期
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesDiabetes Mellitus, Type 2NCT07357740Novo Nordisk A/S400
已完成
2 期
A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be reduced by CagriSema compared to semaglutide, cagrilintide and placebo.2023-505857-42-00Novo Nordisk A/S308